MYGN241220P14000
- 0.40
- 0.000.00%
Myriad Genetics Newsroom
Myriad Genetics Is Maintained at Underperform by B of A Securities
Myriad Genetics Analyst Ratings
BofA Securities Maintains Myriad Genetics(MYGN.US) With Sell Rating, Cuts Target Price to $13
Myriad Genetics Analyst Ratings
Myriad Genetics Initiated at Neutral by UBS
Cautious Hold: Myriad Genetics Faces Growth Uncertainty Amid Reimbursement Challenges
UBS Initiates Myriad Genetics(MYGN.US) With Hold Rating, Announces Target Price $18
Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30
Myriad Genetics Analyst Ratings
Leerink Partners Downgrades Myriad Genetics(MYGN.US) to Hold Rating, Cuts Target Price to $21
Morgan Stanley Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $21
Scotiabank Maintains Myriad Genetics(MYGN.US) With Buy Rating, Cuts Target Price to $24
Myriad Genetics Is Maintained at Neutral by Piper Sandler
Myriad Genetics Analyst Ratings
J.P. Morgan Maintains Myriad Genetics(MYGN.US) With Sell Rating, Cuts Target Price to $15
Piper Sandler Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $24
Analysts Offer Insights on Healthcare Companies: Myriad Genetics (MYGN) and Jazz Pharmaceuticals (JAZZ)
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $20
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $20
Cautious Hold Recommendation for Myriad Genetics Amid GeneSight Coverage Challenges and Mixed Revenue Signals